Casi Pharmaceuticals, Inc. CASIF
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $20.71M, -27.4% YoY · Filed May 15, 2026
Casi Pharmaceuticals, Inc. (CASIF) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $20.7 million and a net loss of $48.1 million. Free cash flow was -$20.8 million. As of Dec 31, 2025 it held $7.3 million in cash and investments and $22.2 million in total debt.
Revenue
$20.71M
-27.4% vs prior year
Net income
$-48.06M
-22.4% vs prior year
Operating cash flow
$-20.75M
+29.0% vs prior year
Free cash flow
$-20.77M
+29.5% vs prior year
EPS
$-2.59
-1.2% vs prior year
Dividend per share
None
Shares outstanding
20.56M
+32.7% vs prior year
Net cash
$-14.89M
FY 2025
Operating margin
-217.3%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CASIF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Beijing, China
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1962738
- Former names
- CASI Pharmaceuticals Holdings, Inc. (until Feb 14, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $20.7M | $28.5M | $33.9M | $38.0M |
| Operating income | -$45.0M | -$39.6M | -$25.1M | -$34.0M |
| Net income | -$48.1M | -$39.3M | -$27.0M | -$41.0M |
| Diluted EPS | -$2.59 | -$2.56 | -$2.02 | -$3.01 |
| Operating cash flow | -$20.8M | -$29.2M | -$20.0M | -$21.1M |
| Free cash flow | -$20.8M | -$29.4M | -$20.2M | -$26.7M |
| Total assets | $25.6M | $53.7M | $75.3M | $96.2M |
| Total liabilities | $62.9M | $51.8M | $51.1M | $29.3M |
| Stockholders' equity | -$37.3M | $1.9M | $24.2M | $44.6M |
| Cash and investments | $7.3M | $15.4M | $30.8M | $53.0M |
| Total debt | $22.2M | $22.1M | $21.2M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 2, 2026 |
| 6-K | Current report (foreign issuer) | Aug 14, 2026 | Aug 14, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Aug 13, 2026 |
| 6-K | Current report (foreign issuer) | Jul 15, 2026 | Jul 15, 2026 |
| 6-K | Current report (foreign issuer) | Jun 29, 2026 | Jun 29, 2026 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 2, 2026 |
All 157 Casi Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.